Skip to content
Clinical Trials – home
GermanyBack to Germany

Clinical trials in Duelmen – page 138

1 729 clinical trials in Duelmen, Germany across 1 research site. Every trial is listed in the EU Clinical Trials Register and updated daily.

GermanyOur site in GermanyKlinischeStudien.de(opens in a new tab)
Duelmen at a glance
1 729
clinical trials
  • Research sites1
Type of trial
Recruitment status
Quick filters

1 729 trials in Duelmen

Open in trial search

Study on Milvexian for Preventing Stroke in Patients with Acute Ischemic Stroke or High-Risk Transient Ischemic Attack

Registered drug
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Acetylsalicylic Acid
  • Sponsor:Janssen Cilag International

Study of Chemotherapy With Pembrolizumab and Olaparib for Patients With Advanced Epithelial Ovarian Cancer Without BRCA Mutation

Registered drug
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Anhydrous Docetaxel
  • Sponsor:Merck Sharp & Dohme LLC

Study comparing tarlatamab with topotecan in patients with relapsed small cell lung cancer after first-line chemotherapy

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Dexamethasone
  • Sponsor:Amgen Inc.

Epilepsy

Not recruiting

Study on Ganaxolone for Children and Adults with Epilepsy Related to Tuberous Sclerosis Complex

InvestigationalNo placebo
Countries:GermanyGermany
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Ganaxolone
  • Sponsor:Marinus Pharmaceuticals Inc.

Pulmonary sarcoidosis

Not recruiting

Study on Efzofitimod for Treating Pulmonary Sarcoidosis in Patients

Registered drug
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Efzofitimod
  • Sponsor:aTYR Pharma Inc.

Ischaemic stroke

Not recruiting

Study on the Safety and Effectiveness of Tenecteplase for Patients with Acute Ischemic Stroke and Incomplete Reperfusion After Mechanical Thrombectomy

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Tenecteplase
  • Sponsor:Insel Gruppe AG

Psoriasis

Not recruiting

Study of Risankizumab and Ustekinumab for Children and Teens with Moderate to Severe Plaque Psoriasis

InvestigationalNo placebo
Countries:GermanyGermany
  • Participants:0–17 years
  • Substances:Risankizumab
  • Sponsor:AbbVie Deutschland GmbH & Co. KG

Lung adenocarcinoma

Not recruiting

Study Comparing Atezolizumab and Drug Combination with Pembrolizumab and Drug Combination for Patients with Advanced Lung Cancer

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Atezolizumab
  • Sponsor:Charite Universitaetsmedizin Berlin KöR

Study on JNJ-81201887 for Treating Geographic Atrophy in Age-related Macular Degeneration Patients

Registered drug
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Onzemipgene parvec
  • Sponsor:Janssen Cilag International

Study of Magrolimab and Chemotherapy for Newly Diagnosed Acute Myeloid Leukemia Patients Eligible for Stem Cell Transplantation

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Cytarabine
  • Sponsor:University of Leipzig

Dermatitis atopic

Not recruiting

Study of Upadacitinib for Adolescents and Adults with Moderate to Severe Eczema

Investigational
Countries:GermanyGermany
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Upadacitinib
  • Sponsor:AbbVie Deutschland GmbH & Co. KG

Malignant melanoma

Not recruiting

Study Comparing MK-7684A (Vibostolimab and Pembrolizumab) with Pembrolizumab for Adults and Children with High-Risk Stage II-IV Melanoma

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Pembrolizumab
  • Sponsor:Merck Sharp & Dohme LLC

Other cities in Germany

The busiest research cities in the country

All 505 cities in Germany

Clinical research in Duelmen

What the registry says about research in the country

01 Immune System Diseases

In Dülmen, several recruiting studies focus on immune system diseases, especially psoriasis and chronic spontaneous urticaria. The research is aimed at finding better ways to control symptoms, assess treatment benefit, and support longer-term disease management.

  • Moderate to severe plaque psoriasis
  • Mild to moderate psoriasis
  • Chronic spontaneous urticaria
  • Evaluating treatment effectiveness and safety

These trials include studies of new therapies and comparisons with established options to improve care for people living with persistent inflammatory skin conditions.

02 Skin and Connective Tissue Diseases

Research in skin and connective tissue diseases is a major part of the local clinical trial landscape, with studies covering atopic dermatitis, acne, and different forms of psoriasis. The overall goal is to test new topical and oral treatments that may offer better symptom relief and disease control.

  • Mild to moderate atopic dermatitis
  • Papulopustular acne
  • Chronic stable plaque psoriasis
  • Comparing new treatments with approved therapies or vehicle

These studies help researchers understand how well candidate treatments reduce skin inflammation, improve visible lesions, and support longer-lasting control of chronic skin disease.

03 Parasitic Diseases

Clinical research also includes parasitic diseases, with scabies being a key focus. The studies are designed to evaluate how well standard therapies work in clearing infection and restoring skin health.

  • Scabies
  • Assessing clinical response after treatment
  • Evaluating symptom resolution and treatment success

This area reflects practical, patient-centered research aimed at confirming effective care for a common contagious skin condition.

04 Topical Treatment Development

A number of trials in the city are centered on topical medicines for inflammatory skin disorders, including gels and ointments for acne, atopic dermatitis, and psoriasis. The focus is on comparing candidate products with approved treatments and non-active controls.

  • Testing new gels and ointments
  • Comparing against reference treatments
  • Improving local symptom control

These studies aim to refine everyday treatment options that may be easier to use and more effective for patients with chronic skin conditions.

05 Long-Term Disease Control

Some research is directed at long-term disease control, looking at how well treatments maintain benefit over time in chronic conditions such as psoriasis and urticaria. This helps determine whether a therapy can keep symptoms from returning or worsening.

  • Tracking time to disease worsening
  • Monitoring treatment durability
  • Supporting chronic disease management

Such studies are especially valuable for people who need sustained relief rather than short-term improvement alone.

Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.